Hari Kumar appointed CEO of Panmira
This article was originally published in Scrip
Executive Summary
Panmira Pharmaceuticals, a small molecule pharmaceutical company focused on novel therapies for inflammatory diseases, has appointed Dr Hari Kumar CEO. Until recently, Dr Kumar served as chief business officer of Amira Pharmaceuticals, where he led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.